Clinical status of agents being developed for leishmaniasis (Q28279390)

Expert Opinion on Investigational Drugs

Europe PubMed Central

title

Clinical status of agents being developed for leishmaniasis (English)

0 references

author name string

Jonathan Berman

series ordinal

1

0 references

language of work or name

English

0 references

publication date

November 2005

0 references

published in

0 references

volume

14

0 references

issue

11

0 references

page(s)

1337-46

0 references

cites work

Trial of oral miltefosine for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1517/13543784.14.11.1337

Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.14.11.1337

Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.14.11.1337

Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.14.11.1337

Estimation of population at risk of infection and number of cases of Leishmaniasis

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Miltefosine for new world cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Compassionate use of sitamaquine in an HIV-positive patient with visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Cutaneous leishmaniasis in a Kosovan child treated with oral fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Itraconazole in the treatment of New World mucocutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala-azar dermal leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337

Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1337